Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neurodegeneration as Early Event in Pathogenesis of Diabetic Retinopathy:Multicentric, Prospective, Ph. II-III,Random.Controlled Trial to Assess Efficacy of Neuroprotective Drugs Administered Topically to Prevent/Arrest Diabetic Retinopathy

NCT01726075 is registered in ClinicalTrials.gov with BCN Peptides as lead sponsor.

NCT NCT01726075
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01726075 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neurodegeneration as Early Event in Pathogenesis of Diabetic Retinopathy:Multicentric, Prospective, Ph. II-III,Random.Controlled Trial to Assess Efficacy of Neuroprotective Drugs Administered Topically to Prevent/Arrest Diabetic Retinopathy
Lead sponsor
BCN Peptides
Phase
Phase 2/3
Overall status
Completed
Start date
February 28, 2013
Completion date
November 30, 2015
Enrollment
450 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic retinopathy